Background: Alpinia oxyphylla (Zingiberaceae), an herbaceous perennial plant, its capsular fruit is commonly used in traditional Chinese
Introduction
Overactive bladder syndrome arises from the involuntary activity of the detrusor muscle during bladder filling. This condition is characterized by the symptoms of nocturia, urinary urgency and increased frequency of micturition with or without incontinence (Abrams et al., 2003) . In China, overactive bladder syndrome has been estimated to occur in nearly 8% of the population and the prevalence of the syndrome increases with advance in age (Zhu, 2009 ). Moreover, a questionnaire on the occurrence of overactive bladder syndrome, constructed by the Peking University People's Hospital in 2006, showed that total prevalence was approximately 26.7% in 1036 Chinese women aged between 18-81 years and 36.0% in those aged 50 and over (Chen et al., 2007) . Therefore, the potential scale of the health economic challenge is readily apparent when the substantial prevalence of overactive bladder syndrome is considered, especially in the ageing society of China.
For the therapy of overactive bladder syndrome, many drugs such as anti-muscarinic agents have exhibited significant clinical benefits (Chapple et al., 2008 the process of screening for naturally occurring substances with therapeutic effects against bladder over-activity in vitro assay system, we found that the 95% ethanol extract of the fruits of A. oxyphylla exhibited significant antimuscarinic activity. Whereafter, two new natural products and nine known phytochemicals including flavonoid, diarylheptanoid and phenolic acid were isolated from the 95% ethanol extract (Qing et al., 2012).
Further investigation is required to clarify whether these isolated compounds can be used to substantiate the pharmacological effects of the ethanol extract? In our preliminary experiments based on the in vitro assay system we found that the chrysin, tectochrysin, kaempherol， yakuchinone A and B, oxyphyllacinol and nootkatone were negative. However, the izalpinin showed the positive results. The chemical structure of izalpinin is shown in Figure 1 .
Figure 1: Chemical structure of izalpinin
This study was undertaken to evaluate the in vitro pharmacological profile of izalpinin on carbachol-induced isolated bladder contraction of rat. Tolterodine was assessed as positive control in the assays. Our results showed that izalpinin was potent in inhibiting carbachol-induced bladder contractions at the designed range of concentrations. These data suggested that izalpinin could be used as a promising lead compound to treat overactive bladder syndrome.
Experimental methods

Materials
Izalpinin was isolated from 95% ethanol extract of A. oxyphylla fruits (Qing et al., 2012) and the purity exceeded 98%. Tolterodine and carbachol were purchased from Hainan HiFly industrial Co.Ltd (Haikou, China). DMSO was obtained from Sigma-Aldrich (St Louis, MO, USA).
KCl, NaCl and other chemicals were purchased from Hainan YiGao Instrument Co. Ltd (Haikou, China).
For the in vitro protocol, izalpinin was prepared at 1 mM in DMSO and dilutions made in de-ionized water for appropriate concentration.
Tolterodine and carbachol were dissolved in de-ionized water. KCl was prepared in 10% DMSO in de-ionized water. Reported concentrations were the final concentrations in the organ-bath solution.
Animals
All rat experiments were performed in accordance with the Institutional Animal Care and Use Committee at the Hainan Medical University Male Sprague-Dawley rats (280-340 g) were purchased from DongChuang Laboratory Animal Service Department (Changsha, China). Rats were maintained under controlled temperature of 24 ± 2°C and relative humidity of 60 ± 10% with a 12-h light/dark cycle. Commercial rat chows were available ad libitum until to the day of experiment. All rats had free access to water.
Bladder detrusor preparation and functional study
The experimental procedures were performed according to protocols modified from previous published methods (Otsuka et al. There are some limitations in the present study. We did not conduct pharmacological in vivo studies to illustrate the role of izalpinin on bladder function in rats or other animals. It will also be of interest to assess the activity of izalpinin on human detrusor specimens. Thus, further investigation is required to clarify whether izalpinin is an effective and safe therapy for the treatment of overactive bladder syndrome in animals and/or human beings.
Conclusion
In summary, izalpinin demonstrated bladder muscarinic receptor antagonistic action on the isolated rat detrusor smooth muscle. This compound might be used as a promising lead compound for the treatment of overactive bladder syndromes.
